VRTX ▼ -0.1% - Vertex Pharmaceuticals Incorporated $VRTX IBKR Goldman Sachs: Updates U.S. Director’s Cut List ? • Goldman Sachs added Vertex Pharmaceuticals to its monthly U.S. Director’s Cut list and removed Interactive Brokers. • The list includes 20–25 high-conviction, Buy-rated U.S. stocks selected for differentiated views and attractive risk-adjusted return potential. • Goldman updates the list monthly based on bottom-up fundamental analysis; additions or removals do not necessarily indicate a change in analyst rating. Goldman Sachs added Vertex Pharmaceuticals to its monthly U.S. Director's Cut list of high-conviction Buy-rated stocks, a recognition of the firm's differentiated positive view on the company's fundamentals and risk-adjusted return potential. Despite the inclusion on this selective list, Vertex shares moved only marginally, declining 0.1% today. 01-SEP-2026 05:37 AM ET